Lungs News and Research

RSS

DiscoveryBioMed receives NIDDK grant for Cystic Fibrosis Corrector Ligand Drug Discovery program

DiscoveryBioMed, Inc. (DBM), a human cell-based drug discovery company, learned recently that its Cystic Fibrosis Corrector Ligand (CFCL) Drug Discovery program will be funded by the NIH. The two-year award will focus on validation and prioritization of several lead CFCL chemical classes, drugs that correct the most common cystic fibrosis (CF) disease-causing mutation.

14 Sep 2011

Celecoxib inhibits GSK3 enzyme in lung cancer cells

Several clinical studies have shown that taking the anti-inflammatory drug celecoxib can reduce the risk of developing polyps that lead to colon cancers, at the cost of increasing the risk of heart disease. But what if this tradeoff was not necessary?

14 Sep 2011

NIH awards Rutgers and UMDNJ $23.2M grant to develop drugs against mustard gas

The National Institutes of Health (NIH) has awarded a five-year $23.2 million grant to a group of investigators at Rutgers University and the University of Medicine and Dentistry of New Jersey (UMDNJ)-Robert Wood Johnson Medical School to continue their research aimed at developing drug products that could be used against chemical warfare agents from a terrorist attack.

14 Sep 2011

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.

14 Sep 2011

New drug combination may treat two aggressive cancers

Researchers at Brigham and Women's Hospital (BWH) have identified a new combination of targeted therapies that, together, may treat two aggressive tumor types that until now have not had effective treatments. These findings are published in Cancer Cell on September 13, 2011.

13 Sep 2011

Researchers identify new type of potential anticancer drug

Researchers at Emory University School of Medicine have identified a new type of potential anticancer drug. The compound, named FOBISIN, targets 14-3-3 proteins, important for the runaway growth of cancer cells.

13 Sep 2011

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Alchemia Limited, today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug HA-Irinotecan in Small Cell Lung Cancer (SCLC). Two patients have received their first doses of therapy. This investigator sponsored trial is being conducted at Monash Cancer Centre, Southern Health and Peninsula Oncology Centre in Melbourne, Victoria.

12 Sep 2011

InterMune to launch Esbriet for German patients with IPF

InterMune, Inc. today announced that Esbriet will be offered to patients in Germany beginning September 15, 2011. This will mark the first time Esbriet will be commercially available in Europe since it was approved by the European Commission in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF), a devastating and fatal lung disease.

12 Sep 2011

Genentech submits vismodegib NDA to FDA for treatment of advanced basal cell carcinoma

Genentech, a member of the Roche Group, today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

12 Sep 2011

IsoRay receives FDA clearance for GliaSite radiation therapy system to treat brain cancer

IsoRay, Inc. announced today that the FDA has cleared its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer.

12 Sep 2011

Crocus plant to provide a tumor killing “smart bomb”

According to the latest research, a drug derived from plant extracts could wipe out tumors in a single treatment with minimal side effects. Scientists have turned a chemical found in crocuses into a ‘smart bomb’ that targets cancerous tumors. The advantage is that healthy tissue is unharmed, reducing the odds of debilitating side effects. And unlike other side effect-free drugs, it is able to kill off more than one type of the disease, including breast, prostate, lung and bowel cancer. Potentially, all solid tumours could be vulnerable to drugs developed this way, meaning it could be used against all but blood cancers.

12 Sep 2011

Lung cancer patients treated in high safety-net burden facilities less likely to undergo surgery

A new study finds that lung cancer patients treated in hospitals that care for a high percentage of uninsured and Medicaid-insured patients, so-called "high safety-net burden facilities," were significantly less likely to undergo surgery that was intended to cure the cancer compared to patients treated at low safety-net burden facilities.

12 Sep 2011

Non-communicable disease epidemic a global problem

Later this month the United Nations will convene a high-level meeting on non-communicable diseases. The world's global health news has been so dominated by infectious culprits - HIV/AIDS, malaria, tuberculosis, influenza - that it's easy to forget just how big a toll conditions like diabetes, cancer and heart and lung disease take say experts.

9 Sep 2011

NIH awards $12.8 million renewal grant for Louisville adult stem cell research project

At the time when Dr. Roberto Bolli received word that he was awarded a $12.8 million grant renewal from the National Institutes of Health for one research project, five patients in another of his clinical trials at the University of Louisville have reached the successful endpoint of their participation.

9 Sep 2011

Landmark discovery in rapid spread of PRL-3 oncoprotein associated aggressive cancers

Scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) have made a landmark discovery in the battle against the rapid spread of aggressive cancers associated with PRL-3 oncoprotein.

9 Sep 2011

Study on insect species associated with Tibetan medicinal fungus, O. sinensis

A team of researchers from the Institute of Microbiology, Chinese Academy of Sciences (Xiao-Liang Wang and Yi-Jian Yao), summarized all the available information on the insect species associated with the Tibetan medicinal fungus Ophiocordyceps sinensis through an extensive literature survey and analyzed their relationships with the fungus. The study was published in the open access journal ZooKeys.

9 Sep 2011

Stage III lung cancer patients can benefit from concurrent chemo and radiation therapy

Nearly 50,000 Americans are diagnosed each year with stage III or locally advanced NSCLC, for which surgery is usually not a viable treatment option. Optimizing nonsurgical treatment strategies for these patients is an ongoing research endeavor.

9 Sep 2011

Pancreatic cancer outcomes poor in UK – experts urge better diagnosis and treatment

A new report reveals that survival rates in the UK for people with pancreatic cancer are among the worst in the world. The report recommends earlier diagnosis and better treatment.

8 Sep 2011

World Cancer Research Fund urges action to stop preventable cancers

According to the WCRF this Wednesday healthier lifestyles and better diets could prevent up to 2.8 million cases of cancer each year. The WCRF called upon governments to “avoid a public health disaster”.

8 Sep 2011

University of Maryland surgeons transplant first lungs treated with experimental repair process

Surgeons at the University of Maryland Medical Center have transplanted the first lungs treated in the United States with an experimental repair process before transplantation. The procedure is part of a five-center national clinical research trial to evaluate the efficacy of repairing, before transplant, lungs that might otherwise have been passed over as unsuitable for organ donation.

8 Sep 2011

Lungs News and Research

DiscoveryBioMed receives NIDDK grant for Cystic Fibrosis Corrector Ligand Drug Discovery program

Celecoxib inhibits GSK3 enzyme in lung cancer cells

NIH awards Rutgers and UMDNJ $23.2M grant to develop drugs against mustard gas

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

New drug combination may treat two aggressive cancers

Researchers identify new type of potential anticancer drug

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

InterMune to launch Esbriet for German patients with IPF

Genentech submits vismodegib NDA to FDA for treatment of advanced basal cell carcinoma

IsoRay receives FDA clearance for GliaSite radiation therapy system to treat brain cancer

Crocus plant to provide a tumor killing “smart bomb”

Lung cancer patients treated in high safety-net burden facilities less likely to undergo surgery

Non-communicable disease epidemic a global problem

NIH awards $12.8 million renewal grant for Louisville adult stem cell research project

Landmark discovery in rapid spread of PRL-3 oncoprotein associated aggressive cancers

Study on insect species associated with Tibetan medicinal fungus, O. sinensis

Stage III lung cancer patients can benefit from concurrent chemo and radiation therapy

Pancreatic cancer outcomes poor in UK – experts urge better diagnosis and treatment

World Cancer Research Fund urges action to stop preventable cancers

University of Maryland surgeons transplant first lungs treated with experimental repair process

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News